Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Biofrontera Inc (BFRI)

Biofrontera Inc (BFRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026 GlobeNewswire - Wed Aug 5, 3:15PM CDT

WOBURN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S. specialty dermatology company commercializing Ameluz ® (aminolevulinic acid...

BFRI : 1.2500 (+2.46%)
BFRIW : 0.0233 (-21.28%)
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 GlobeNewswire - Thu May 21, 8:15AM CDT

WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization...

BFRI : 1.2500 (+2.46%)
BFRIW : 0.0233 (-21.28%)
Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update GlobeNewswire - Thu May 14, 6:30AM CDT

Woburn, MA, May 14, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy...

BFRI : 1.2500 (+2.46%)
BFRIW : 0.0233 (-21.28%)
Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis GlobeNewswire - Wed May 13, 8:00AM CDT

The second annual #HatsonforAK Campaign runs May 18–24, 2026, culminating on Global Actinic Keratosis (AK) Awareness Day This social media–driven initiative invites people to wear a hat, share a photo,...

BFRI : 1.2500 (+2.46%)
BFRIW : 0.0233 (-21.28%)
Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026 GlobeNewswire - Fri May 8, 3:00PM CDT

WOBURN, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”) , a biopharmaceutical company specializing in the development and commercialization...

BFRI : 1.2500 (+2.46%)
BFRIW : 0.0233 (-21.28%)
Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update GlobeNewswire - Thu Mar 19, 8:25AM CDT

Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA, March 19, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing...

BFRI : 1.2500 (+2.46%)
BFRIW : 0.0233 (-21.28%)
Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026 GlobeNewswire - Mon Mar 9, 4:25PM CDT

WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”) , a biopharmaceutical company specializing in the development and commercialization...

BFRI : 1.2500 (+2.46%)
BFRIW : 0.0233 (-21.28%)
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris  GlobeNewswire - Mon Mar 9, 8:15AM CDT

• Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz ® PDT versus vehicle • 3-hour incubation regimen identified as the most promising protocol for further...

BFRI : 1.2500 (+2.46%)
BFRIW : 0.0233 (-21.28%)
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable GlobeNewswire - Thu Feb 26, 8:15AM CST

WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (“PDT”),...

BFRI : 1.2500 (+2.46%)
BFRIW : 0.0233 (-21.28%)
Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities GlobeNewswire - Tue Feb 17, 8:15AM CST

Phase 1 maximal-use pharmacokinetics (PK) study completed in support of planned U.S. label expansion Data to complement previously announced positive Phase 3 efficacy results on extremities, neck and...

BFRI : 1.2500 (+2.46%)
BFRIW : 0.0233 (-21.28%)

Barchart Exclusives

Target Appoints Its First-Ever AI Exec as the Retailer Pushes Deeper Into Artificial Intelligence. What It Means for TGT Stock. Barchart - Wed Aug 12, 6:30PM CDT
Target appointed Chandhu Nair as its first chief artificial intelligence officer, effective Aug. 24, as the retailer expands its use of AI across inventory, operations, and customer experience. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.